SMMT

Over the past six months, Summit Therapeutics' stock has been influenced by several key events. In September 2026, the company presented updated overall survival (OS) results from the global Phase III HARMONi clinical trial and HARMONi-2 data for ivonescimab at the IASLC 2026 World Conference on Lung Cancer, highlighting consistent positive OS trends and efficacy/safety profiles in both Western and Asian patients. Earlier, in August 2026, Summit's partner Akeso announced that ivonescimab achieved its primary overall survival endpoint in a China-only Phase III trial for first-line biliary tract cancer, marking the fourth ivonescimab study to show an overall survival benefit. Analyst ratings and price targets have also impacted the stock; in September 2026, Jefferies upgraded Summit Therapeutics to 'Buy' and raised its price target to $25 from $15, while UBS reiterated a 'Buy' rating with a $33 price target, and Cantor Fitzgerald reiterated an 'Overweight' rating. Conversely, HC Wainwright reiterated a 'Neutral' rating in September 2026. The stock has seen a 28.02% increase in the past month and a 35.26% rise over the last 30 days, though it experienced a 10.81% decrease over the last 12 months.